Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
DNA binding domain
androgen receptor
antagonist
molecular docking
prostate cancer
virtual screening
Journal
Acta pharmacologica Sinica
ISSN: 1745-7254
Titre abrégé: Acta Pharmacol Sin
Pays: United States
ID NLM: 100956087
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
22
12
2020
accepted:
24
02
2021
pubmed:
27
3
2021
medline:
19
3
2022
entrez:
26
3
2021
Statut:
ppublish
Résumé
Androgen receptor (AR), a ligand-activated transcription factor, is a master regulator in the development and progress of prostate cancer (PCa). A major challenge for the clinically used AR antagonists is the rapid emergence of resistance induced by the mutations at AR ligand binding domain (LBD), and therefore the discovery of novel anti-AR therapeutics that can combat mutation-induced resistance is quite demanding. Therein, blocking the interaction between AR and DNA represents an innovative strategy. However, the hits confirmed targeting on it so far are all structurally based on a sole chemical scaffold. In this study, an integrated docking-based virtual screening (VS) strategy based on the crystal structure of the DNA binding domain (DBD) of AR was conducted to search for novel AR antagonists with new scaffolds and 2-(2-butyl-1,3-dioxoisoindoline-5-carboxamido)-4,5-dimethoxybenzoicacid (Cpd39) was identified as a potential hit, which was competent to block the binding of AR DBD to DNA and showed decent potency against AR transcriptional activity. Furthermore, Cpd39 was safe and capable of effectively inhibiting the proliferation of PCa cell lines (i.e., LNCaP, PC3, DU145, and 22RV1) and reducing the expression of the genes regulated by not only the full-length AR but also the splice variant AR-V7. The novel AR DBD-ARE blocker Cpd39 could serve as a starting point for the development of new therapeutics for castration-resistant PCa.
Identifiants
pubmed: 33767381
doi: 10.1038/s41401-021-00632-5
pii: 10.1038/s41401-021-00632-5
pmc: PMC8724294
doi:
Substances chimiques
AR protein, human
0
Androgen Receptor Antagonists
0
Receptors, Androgen
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-239Informations de copyright
© 2021. The Author(s), under exclusive licence to CPS and SIMM.
Références
J Comput Aided Mol Des. 2000 Mar;14(3):251-64
pubmed: 10756480
Clin Cancer Res. 2016 Jun 1;22(11):2744-54
pubmed: 26712685
Prostate. 2007 Mar 1;67(4):416-26
pubmed: 17219378
ACS Chem Biol. 2014 Mar 21;9(3):692-702
pubmed: 24354286
Cancer Res. 2009 Mar 15;69(6):2305-13
pubmed: 19244107
Nat Chem Biol. 2010 Nov;6(11):829-36
pubmed: 20890287
J Chem Theory Comput. 2011 Feb 8;7(2):525-37
pubmed: 26596171
J Med Chem. 2014 Aug 14;57(15):6458-67
pubmed: 25062331
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
J Med Chem. 2010 Apr 8;53(7):2719-40
pubmed: 20131845
Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11667-72
pubmed: 19571010
Nat Rev Drug Discov. 2003 Apr;2(4):259-66
pubmed: 12669025
In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9
pubmed: 10462204
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
J Mol Biol. 1997 Apr 4;267(3):727-48
pubmed: 9126849
J Biol Chem. 2014 Sep 19;289(38):26417-26429
pubmed: 25086042
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W316-22
pubmed: 21715386
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6201-6
pubmed: 15833816
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4758-63
pubmed: 15037741
Eur Urol. 2010 Sep;58(3):464-5
pubmed: 20845529
Nucleic Acids Res. 2002 Jan 1;30(1):38-41
pubmed: 11752248
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
Cancer J. 2013 Jan-Feb;19(1):43-9
pubmed: 23337756
Endocrinology. 2006 Jan;147(1):590-8
pubmed: 16210365
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Nat Med. 2004 Jan;10(1):33-9
pubmed: 14702632
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
Annu Rev Med. 2013;64:1-13
pubmed: 23020876
Clin Cancer Res. 2013 Nov 15;19(22):6067-73
pubmed: 24141628
PLoS One. 2011 Apr 28;6(4):e19059
pubmed: 21552559
Cancer Lett. 2018 Nov 28;437:35-43
pubmed: 30165195
Med Res Rev. 2019 Sep;39(5):1485-1514
pubmed: 30569509
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
J Med Chem. 2012 Feb 23;55(4):1635-44
pubmed: 22280402
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Endocr Relat Cancer. 2013 May 20;20(3):R83-99
pubmed: 23456430
Sci China Life Sci. 2018 May;61(5):550-558
pubmed: 29119376
Chem Biol. 2014 Nov 20;21(11):1476-85
pubmed: 25459660
Toxicol Sci. 2009 Aug;110(2):341-52
pubmed: 19465456
J Chem Inf Model. 2017 May 22;57(5):1018-1028
pubmed: 28441481
Cancer Discov. 2013 Sep;3(9):1020-9
pubmed: 23779130
Genomics Proteomics Bioinformatics. 2018 Dec;16(6):416-427
pubmed: 30639122
Pharmacol Ther. 2013 Dec;140(3):223-38
pubmed: 23859952
J Med Chem. 2014 Aug 14;57(15):6867-72
pubmed: 25025737
Trends Biochem Sci. 2001 Jun;26(6):384-90
pubmed: 11406412
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11890-5
pubmed: 12185249
Nat Biotechnol. 2015 Mar;33(3):243-6
pubmed: 25748911
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Acta Pharmacol Sin. 2015 Jan;36(1):3-23
pubmed: 24909511
Cancer Res. 2008 Jul 1;68(13):5469-77
pubmed: 18593950
J Comput Chem. 2005 Dec;26(16):1752-80
pubmed: 16211539
J Comput Aided Mol Des. 2007 Dec;21(12):681-91
pubmed: 17899391
Cancer Res. 2013 Jan 15;73(2):483-9
pubmed: 23117885
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142